SCHEMBL13259773

SCHEMBL13259773

N#Cc1cnc(N[C@H]2CCCNC2)c2nc(-c3ccc(Cl)cc3)cn12

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 16/20 0.69
▸ MAPKAPK2 P49137 7/20 0.69
▸ IRAK4 Q9NWZ3 4/20 0.48
▸ LCK P06239 2/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ IGF1R P08069 1/20 0.48
▸ CSNK1D P48730 1/20 0.48
▸ TSSK2 Q96PF2 1/20 0.48
▸ RET P07949 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ CDK7 P50613 1/20 0.44
▸ BLK P51451 1/20 0.44
▸ IRAK1 P51617 1/20 0.44
▸ CCNH P51946 1/20 0.44
▸ SRPK1 Q96SB4 1/20 0.44
▸ PDPK1 O15530 1/20 0.44
▸ RPS6KB1 P23443 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13259792 0.89 CHEK1 (0.67) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13258798 0.88 CHEK1 (0.55) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13258778 0.86 CHEK1 (0.56) CHEK1MAPKAPK2IRAK4LCKRET
SCHEMBL13259782 0.83 CHEK1 (0.49) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13259783 0.82 CHEK1 (1.00) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13764316 0.82 CHEK1 (1.00) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13258780 0.80 MAPKAPK2 (0.46) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13764317 0.75 CHEK1 (0.47) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13776797 0.75 CHEK1 (0.55) CHEK1MAPKAPK2IRAK4LCKJAK2
SCHEMBL13259850 0.73 CHEK1 (0.57) CHEK1MAPKAPK2IRAK4LCKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010088368-A2 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2010-08-05 — — WO disclosed
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2009-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A CHEK1 1/4885MAPKAPK2 43/4885IRAK4 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback